Clinical validation of breast cancer biomarkers using tissue microarray technology

Iram Quraishi, Mazhar Rishi, Michael Feldman, Michael J Wargovich, Barbara Weber

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume15
Issue number1
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Tumor Biomarkers
Breast Neoplasms
Oligonucleotide Array Sequence Analysis
Technology
Antigens
Ductal Carcinoma
Carcinoma, Intraductal, Noninfiltrating
Antibodies
Carcinoma, Ductal, Breast
Validation Studies
Neoplasm Genes
Genetic Association Studies
Progesterone Receptors
Microarray Analysis
Transcriptome
Estrogen Receptors
Colon
Proteins
Adenocarcinoma
Epithelium

ASJC Scopus subject areas

  • Anatomy
  • Medical Laboratory Technology

Cite this

Clinical validation of breast cancer biomarkers using tissue microarray technology. / Quraishi, Iram; Rishi, Mazhar; Feldman, Michael; Wargovich, Michael J; Weber, Barbara.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 15, No. 1, 03.2007, p. 45-49.

Research output: Contribution to journalArticle

Quraishi, Iram ; Rishi, Mazhar ; Feldman, Michael ; Wargovich, Michael J ; Weber, Barbara. / Clinical validation of breast cancer biomarkers using tissue microarray technology. In: Applied Immunohistochemistry and Molecular Morphology. 2007 ; Vol. 15, No. 1. pp. 45-49.
@article{2334b3ba89e14cc4a52c3aa9dc75cbb6,
title = "Clinical validation of breast cancer biomarkers using tissue microarray technology",
abstract = "The results of previous studies done in our laboratory on breast cancer gene expression profile, using DNA microarrays, led to the discovery of several genes associated with breast cancer progression. Further evaluation of these genes and their involvement at various stages of cancer progression required performance of immunohistochemistry on thousands of different tissue blocks. Tissue microarray (TMA) technology facilitates rapid translation of DNA microarrays results to clinical specimens by using immunohistochemical analysis of protein expression. DNA microarray analysis done in our laboratory showed a significantly higher expression of prostatic-specific antigen (PSA) in invasive ductal carcinomas as compared to ductal carcinoma in situ, a finding contrary to the previously published data for PSA immunoreactivity in breast carcinomas. To find out whether TMA strategy could be used to explore the expression of the candidate genes involved in the breast cancer progression, we constructed a breast cancer progression TMA. It consisted of 2 normal ductal epithelium, 8 ductal carcinoma in situ, 19 invasive ductal carcinomas, and 3 metastatic ductal carcinomas of breast in triplets. Two prostatic adenocarcinomas and 2 normal colons were used as positive and negative controls, respectively. We first used well-documented and well-tested markers, such as antibodies to estrogen receptor, progesterone receptor, and p53. Results of these 3 antibodies were according to the previously published data. To validate our result, we then used antibody to PSA and looked for the expression of this protein on breast cancer progression TMA. Except for the 2 positive controls all 98 cores were found to be negative for PSA expression highlighting the importance of validation studies for DNA microarray results.",
keywords = "Breast cancer progression tissue microarrays, DNA microarrays, Immunohistochemistry, Prostatic-specific antigen",
author = "Iram Quraishi and Mazhar Rishi and Michael Feldman and Wargovich, {Michael J} and Barbara Weber",
year = "2007",
month = "3",
doi = "10.1097/01.pai.0000213129.86288.34",
language = "English",
volume = "15",
pages = "45--49",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical validation of breast cancer biomarkers using tissue microarray technology

AU - Quraishi, Iram

AU - Rishi, Mazhar

AU - Feldman, Michael

AU - Wargovich, Michael J

AU - Weber, Barbara

PY - 2007/3

Y1 - 2007/3

N2 - The results of previous studies done in our laboratory on breast cancer gene expression profile, using DNA microarrays, led to the discovery of several genes associated with breast cancer progression. Further evaluation of these genes and their involvement at various stages of cancer progression required performance of immunohistochemistry on thousands of different tissue blocks. Tissue microarray (TMA) technology facilitates rapid translation of DNA microarrays results to clinical specimens by using immunohistochemical analysis of protein expression. DNA microarray analysis done in our laboratory showed a significantly higher expression of prostatic-specific antigen (PSA) in invasive ductal carcinomas as compared to ductal carcinoma in situ, a finding contrary to the previously published data for PSA immunoreactivity in breast carcinomas. To find out whether TMA strategy could be used to explore the expression of the candidate genes involved in the breast cancer progression, we constructed a breast cancer progression TMA. It consisted of 2 normal ductal epithelium, 8 ductal carcinoma in situ, 19 invasive ductal carcinomas, and 3 metastatic ductal carcinomas of breast in triplets. Two prostatic adenocarcinomas and 2 normal colons were used as positive and negative controls, respectively. We first used well-documented and well-tested markers, such as antibodies to estrogen receptor, progesterone receptor, and p53. Results of these 3 antibodies were according to the previously published data. To validate our result, we then used antibody to PSA and looked for the expression of this protein on breast cancer progression TMA. Except for the 2 positive controls all 98 cores were found to be negative for PSA expression highlighting the importance of validation studies for DNA microarray results.

AB - The results of previous studies done in our laboratory on breast cancer gene expression profile, using DNA microarrays, led to the discovery of several genes associated with breast cancer progression. Further evaluation of these genes and their involvement at various stages of cancer progression required performance of immunohistochemistry on thousands of different tissue blocks. Tissue microarray (TMA) technology facilitates rapid translation of DNA microarrays results to clinical specimens by using immunohistochemical analysis of protein expression. DNA microarray analysis done in our laboratory showed a significantly higher expression of prostatic-specific antigen (PSA) in invasive ductal carcinomas as compared to ductal carcinoma in situ, a finding contrary to the previously published data for PSA immunoreactivity in breast carcinomas. To find out whether TMA strategy could be used to explore the expression of the candidate genes involved in the breast cancer progression, we constructed a breast cancer progression TMA. It consisted of 2 normal ductal epithelium, 8 ductal carcinoma in situ, 19 invasive ductal carcinomas, and 3 metastatic ductal carcinomas of breast in triplets. Two prostatic adenocarcinomas and 2 normal colons were used as positive and negative controls, respectively. We first used well-documented and well-tested markers, such as antibodies to estrogen receptor, progesterone receptor, and p53. Results of these 3 antibodies were according to the previously published data. To validate our result, we then used antibody to PSA and looked for the expression of this protein on breast cancer progression TMA. Except for the 2 positive controls all 98 cores were found to be negative for PSA expression highlighting the importance of validation studies for DNA microarray results.

KW - Breast cancer progression tissue microarrays

KW - DNA microarrays

KW - Immunohistochemistry

KW - Prostatic-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=34247642336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247642336&partnerID=8YFLogxK

U2 - 10.1097/01.pai.0000213129.86288.34

DO - 10.1097/01.pai.0000213129.86288.34

M3 - Article

VL - 15

SP - 45

EP - 49

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 1

ER -